Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06476795 · ClinicalTrials.gov registry record · NA
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
A NA study of Cardiovascular Diseases and Adiposity, sponsored by University of California, Davis.
- Recruiting
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06476795: Recruiting NA study of Cardiovascular Diseases and Adiposity, sponsored by University of California, Davis.
NCT06476795 is a NA study of Cardiovascular Diseases and Adiposity that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 5 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06476795, a NA study of Cardiovascular Diseases and Adiposity, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
Recently a dietary recommendation of 400 - 600 mg/ day has been proposed for the reduced risk of developing cardiovascular disease. Dietary flavanols can be obtained from the intake of foods such as tea, cocoa, wine, berries and apples. Incorporating Chardonnay Marc (the skins and seeds of Chardonnay grapes) into the diet can be an additional source of dietary flavanols. Like other flavanol-rich foods, Chardonnay Marc provides fiber and polysaccharides that may benefit gut health. This study seeks pilot data on the impact of the daily incorporation of Chardonnay Marc powder into the diet on markers of gut and cardiometabolic health.
Primary Outcome
Microvascular function measured by peripheral arterial tonometry
Conditions Studied
Interventions
- OTHER Chardonnay Marc
Study Locations (1)
California
- University of California, Davis - Davis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2026-06 |
| Phase | NA |
What NCT06476795 shows while recruiting
NCT06476795 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Chardonnay Marc is the first listed.
NCT06476795 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06476795 about?
NCT06476795 is a clinical study titled "The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health". Recently a dietary recommendation of 400 - 600 mg/ day has been proposed for the reduced risk of developing cardiovascular disease. Dietary flavanols can be obtained from the intake of foods such as tea, cocoa, wine, berries and apples. Incorporating Chardonnay Marc (the skins and seeds of Chardonna...
What is the current status of trial NCT06476795?
This trial is currently recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2024-06-01. Estimated completion is 2026-06.
What conditions does trial NCT06476795 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Adiposity, Cardiometabolic Syndrome.
What interventions are being tested in trial NCT06476795?
The interventions under investigation include: Chardonnay Marc (OTHER).
Who is sponsoring clinical trial NCT06476795?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06476795 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06476795's enrollment target sits among peer trials
5 298th of 300 higher than 1 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI